Core Viewpoint - The decline in coal prices is in line with expectations, and the sector shows strong resilience, indicating that there is no need for concern regarding coal prices. The off-peak season may not be as weak as anticipated, and investment in coal stocks should focus on alpha opportunities rather than beta, with high dividends and transformation prospects being key themes throughout the year [1][3]. Investment Highlights - The significant drop in the CCTD reference price for Q5500 coal to 900 RMB/ton from 1020 RMB/ton reflects a decrease of 120 RMB, aligning with the government's price control measures. The coal sector experienced a slight adjustment, with CS coal down by 1.25%, showing relative resilience compared to the Shanghai and Shenzhen 300 index [2]. - The government’s control over coal prices, alongside measures such as increased production and port adjustments, is expected to stabilize the coal market. Anticipation of the upcoming Two Sessions and the 20th National Congress later in the year suggests that supply capacity will be maintained, supporting coal prices. Additionally, the benchmark price for Indonesian thermal coal rose to 188.4 USD/ton, which translates to a domestic cost exceeding 1237 RMB/ton, likely increasing demand for domestic coal [2]. - In 2022, investment in coal stocks should not overly focus on coal prices and government controls. Instead, identifying alpha opportunities through high dividends and transformation potential is crucial. The long-term contract price for Qinhuangdao Q5500 coal in February was 725 RMB/ton, indicating a significant year-on-year increase. This suggests a sustainable optimization of capital expenditure, cash flow, and dividends, with new dividend plans expected following the annual reports in March [3]. Investment Recommendations - The coal sector is currently at a perceived bottom with low valuations. With the expected increase in long-term contract prices for thermal coal and coking coal, high-quality resource companies are seen as having long-term value, while transformation-focused companies offer growth potential. The sector is poised for valuation improvement [4]. - Recommended investment themes include high dividends, green energy transformation, and growth-oriented coal chemical companies. Specific recommendations include China Shenhua, Jingyuan Coal Electricity, Electric Power Investment Energy, Yanzhou Coal, China Xuyang Group, and Baofeng Energy. Additionally, high-quality resource companies such as Shaanxi Coal and Chemical Industry, Huaibei Mining, China Coal Energy, Shanxi Coking Coal, Lu'an Environmental Energy, Lanhua Sci-Tech, Panjiang Coal, and Pingmei Shenma are also recommended [4].

证券研究报告：有色金属 | 公司点评报告 发布时间：2025-05-19 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 13.27 | | --- | --- | | 总股本/流通股本（亿股）48.47 | / 48.47 | | 总市值/流通市值（亿元）643 | / 643 | | 52 周内最高/最低价 | 18.17 / 11.96 | | 资产负债率(%) | 41.5% | | 市盈率 | 18.96 | | 第一大股东 | 中国黄金集团有限公司 | 研究所 分析师:李帅华 SAC 登记编号:S1340522060001 Email:lishuaihua@cnpsec.com 研究助理:杨丰源 SAC 登记编号:S1340124050015 Email:yangfengyuan@cnpsec.com 中金黄金(600489) 24 年年报以及 25 年一季报点评：业绩有序释放， 高分红彰显投资价值 l 25 年 Q1 归母净利润 10.38 亿元，同比+33% 公司发布 2024 年年报及 2025 年一季报。2024 年公司实现营收 655.56 亿元，同 ...

Investment Rating - The industry investment rating is "Positive" [1] Core Viewpoints - The second quarter is recommended for the traditional Chinese medicine sector, with expectations for a performance turning point despite significant pressure in the first quarter [3][10] - The traditional Chinese medicine sector is anticipated to see a recovery in performance due to improved inventory levels and profitability, alongside favorable conditions from U.S. tariff policies [5][21] Summary by Sections 1. Quarterly Report Overview - The first quarter faced substantial pressure, but nearly half of the companies (31) achieved positive growth in net profit attributable to shareholders after excluding non-recurring items, with 18 companies reporting revenue growth [13][14] - Companies such as Jia Ying Pharmaceutical and Te Yi Pharmaceutical reported significant revenue growth of 28.8% and 79.3%, respectively, driven by channel expansion and marketing reforms [14] 2. Core Indicator Tracking - Inventory levels have decreased, leading to sustained improvements in profitability [18] - The traditional Chinese medicine sector's valuation is currently below the average since 2021, indicating potential for recovery [24] 3. Investment Recommendations - Companies with strong brand power and potential for margin improvement are recommended for aggressive investment, including Dong E E Jiao, Tong Ren Tang, and Pian Zai Huang [10][18] - Defensive investments are suggested in stable dividend-paying assets such as Yunnan Baiyao and Ling Rui Pharmaceutical [10][18] - The sector's overall valuation is low, with a TTM price-to-earnings ratio of 27.00x as of May 9, 2025, which is below the average since 2021 [24]

Group 1 - The core viewpoint of the article emphasizes the importance of understanding fund selection rules and market timing to avoid significant investment losses [1][3][4] - The China Securities Regulatory Commission (CSRC) is promoting reforms in public funds, encouraging the development of "low-volatility" products and faster registration for index funds, such as ETFs [1][6] - Historical performance data shows a stark contrast in annualized returns between different indices, highlighting the potential impact of fund selection on long-term investment outcomes [1] Group 2 - The first pitfall in fund selection is not understanding the fund's rules, which can lead to poor investment decisions, such as buying high and selling low [3][4] - The second pitfall involves purchasing funds at high prices during market peaks, which can result in significant losses, especially if the investor follows market trends without considering valuations [4][6] - Recommendations for fund selection include focusing on funds with rules favoring low valuations and high dividends, buying during low market valuations, and cautiously testing new funds with reliable rules [6]

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 22.5 CNY [5]. Core Views - The company maintains a high dividend level and emphasizes the progress of the Yulong Copper Mine Phase III expansion [8]. - The company achieved a revenue of 50.03 billion CNY in 2024, a year-on-year increase of 17%, and a net profit of 2.93 billion CNY, up 5% year-on-year [1]. - In Q1 2025, the company reported a revenue of 16.54 billion CNY, a year-on-year increase of 51%, and a net profit of 808 million CNY, up 10% year-on-year [1]. Production and Performance Summary - In 2024, the company exceeded its copper production target with a total of 177,543 tons, a 35% increase year-on-year, and a completion rate of 112% [2]. - The average copper price in 2024 was 74,932 CNY/ton, reflecting a 9.7% year-on-year increase [2]. - The company plans to produce 168,208 tons of copper in 2025, with a slight year-on-year increase [4]. Financial Forecast - The company aims to achieve total revenue of 55 billion CNY and a total profit of 5 billion CNY in 2025 [8]. - Revenue projections for 2025-2027 are 61.29 billion CNY, 63.08 billion CNY, and 65.70 billion CNY, respectively, with net profits of 3.57 billion CNY, 3.87 billion CNY, and 4.10 billion CNY [9]. - The projected earnings per share (EPS) for 2025-2027 are 1.50 CNY, 1.62 CNY, and 1.72 CNY, respectively [9]. Production Plans - The company plans to increase its lead and zinc production in 2025, with a target of 65,672 tons of lead and 124,581 tons of zinc, both showing year-on-year growth [4]. - The Yulong Copper Mine's processing capacity has been upgraded to 22.8 million tons per year, with ongoing expansion projects [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company demonstrates resilience in its operating performance and continues to provide high dividends [2] - The company is expected to achieve revenue growth driven by multiple projects, maintaining a "Buy" rating [9] Financial Performance Summary - In 2024, the company achieved operating revenue of 236.3 billion yuan, a year-on-year increase of 0.6%, and a net profit attributable to shareholders of 7.044 billion yuan, up 2.0% year-on-year [4] - The company's cash flow from operating activities was 22.7 billion yuan, a decrease of 3.4% year-on-year [4] - The gross margin was 9.9%, down 1.4 percentage points year-on-year, while the net margin improved by 0.04 percentage points to 3.0% [4] Segment Performance - In 2024, revenue from refining products was 108.1 billion yuan, down 10% year-on-year, with a gross margin of 13.1% [4] - PTA revenue was 68.1 billion yuan, down 6% year-on-year, with a gross margin of 3.4% [4] - New materials revenue increased by 22% year-on-year to 41.8 billion yuan, with a gross margin of 14.1% [4] Future Projections - The company is projected to achieve revenues of 248.5 billion yuan in 2025, 264 billion yuan in 2026, and 276.3 billion yuan in 2027 [9] - Net profit is expected to reach 8.742 billion yuan in 2025, 9.735 billion yuan in 2026, and 11.540 billion yuan in 2027 [9] - The projected P/E ratios are 12 for 2025, 11 for 2026, and 9 for 2027 [9] Dividend Policy - The company plans to distribute a cash dividend of 0.45 yuan per share in 2024, totaling 3.168 billion yuan, with a payout ratio of 45% [7] - The focus will shift towards optimizing operations, reducing debt, and enhancing dividends following the peak of capital expenditures [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to see a gradual recovery in performance throughout 2025, with a focus on high dividend returns to shareholders [8] - The jewelry industry is currently facing significant sales pressure due to rising gold prices, which has impacted the company's performance [8] - The company has reported a significant increase in gross margin, attributed to rising gold prices and improved product mix [8] Financial Performance Summary - Total revenue for 2023 is projected at 16,290 million, with a decline to 13,891 million in 2024, followed by a recovery to 15,225 million in 2025 [1] - Net profit attributable to shareholders is expected to decrease from 1,316 million in 2023 to 1,010 million in 2024, with a slight recovery to 1,112 million in 2025 [1] - The latest diluted EPS is forecasted to be 0.92 in 2024, increasing to 1.01 in 2025 [1] Revenue and Profitability Metrics - The gross margin for 2024 is expected to be 20.80%, improving to 26.21% in Q1 2025 [8] - The net profit margin for 2024 is projected at 7.27%, with an increase to 9.43% in Q1 2025 [8] - The company aims for a cumulative cash distribution of at least 50% of its distributable profits over any three consecutive years [8] Channel Performance - Self-operated and e-commerce channels have shown relatively better performance, while the number of terminal stores has decreased [8] - In Q1 2025, self-operated offline revenue was 5.27 billion, e-commerce revenue was 5.34 billion, and franchise revenue was 5.84 billion, reflecting varying performance across product categories [8] Future Outlook - The company anticipates a sequential improvement in performance starting from Q2 2025, supported by a low base effect [8] - The forecast for net profit for 2025 has been adjusted to 11.1 billion, with a new projection for 2027 at 13.1 billion [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to see a gradual recovery in performance throughout 2025, following a challenging 2024 due to pressures in the gold jewelry industry [8] - The company has a strong dividend policy, committing to distribute at least 50% of its cumulative distributable profits in cash over any three consecutive years [8] - Despite a decline in revenue and net profit in 2024, the company anticipates a return to growth in 2025, with quarterly improvements expected starting from Q2 2025 [8] Financial Performance Summary - Total revenue for 2024 is projected at 13.89 billion yuan, a decrease of 14.73% year-on-year, with a net profit of 1.01 billion yuan, down 23.25% [8] - For Q1 2025, revenue is expected to be 2.673 billion yuan, reflecting a 47.3% decline year-on-year, with a net profit of 252 million yuan, down 26.1% [8] - The gross margin improved significantly, with 2024 gross margin at 20.80% (up 2.6 percentage points) and Q1 2025 gross margin at 26.21% (up 10.6 percentage points) [8] - The company’s net profit margin for 2024 is 7.27%, slightly down from the previous year, while Q1 2025 shows an increase to 9.43% [8] Revenue and Profit Forecast - Revenue is expected to grow to 15.23 billion yuan in 2025, with a year-on-year increase of 9.60%, and net profit is projected to reach 1.11 billion yuan, up 10.07% [1][8] - The company’s earnings per share (EPS) is forecasted to be 1.01 yuan in 2025, with a price-to-earnings (P/E) ratio of 12.84 based on the latest diluted EPS [1][8] Market Data - The closing price of the stock is 13.03 yuan, with a market capitalization of approximately 14.28 billion yuan [5] - The company has a price-to-book (P/B) ratio of 2.16 and a net asset value per share of 6.03 yuan [5][6]

一家公司的股东回报政策往往是衡量其价值的第一道标尺，迈瑞医疗这份刚刚发布的2024年报，再次刷 新了市场对"高分红"的认知，同时公司也表达出用AI加速转型的决心。 2025年4月28日晚间，迈瑞医疗公布2024年年报及2025年一季报，公司在2024年营收净利同比正增长，但 在宏观环境出现巨大变化之下，25Q1出现同比出现负增长。然而相较于24Q4，Q1公司业绩环比已大幅改 善，经营质量持续提升。 截至一季报期末，公司现金余额超过159亿元；公司2024年全年累计派发现金红利总额达到76.02亿元，分 红比例为65.15% ；此外公司拟以25Q1末股本基数，实施25年第一次中期分红，金额17.10亿元。公司在行 业面临更多挑战的当下，延续了高分红传统，并计划在2025年新增中期分红，进一步提升资金回馈的灵 活性与频率。 值得关注的是，在延续高分红传统的同时，迈瑞正加速推进AI战略布局。2024年12月，公司发布全球首 个临床落地的重症医疗大模型——"启元"，标志着从传统设备供应商向智能医疗解决方案提供商的战略 转型迈出关键一步。 这种在保持高分红传统的同时积极拥抱技术创新的模式，正在重塑医疗器械企业的价值体系 ...

Core Viewpoint - Aimer Co., Ltd. reported a significant decline in both revenue and net profit for the fiscal year 2024, indicating severe challenges due to weak consumer demand and intensified industry competition [3][4]. Financial Performance - In 2024, Aimer's total revenue was 3.163 billion yuan, a year-on-year decrease of 7.71% - The net profit attributable to shareholders was 163 million yuan, down 46.56% year-on-year, falling short of market expectations [3][4]. - For Q1 2025, Aimer's revenue was 854 million yuan, a decline of 2.86% year-on-year, with net profit at 85.56 million yuan, down 20.26% year-on-year [5]. Business Structure - Revenue from core product lines saw varying degrees of decline, with lingerie revenue down 15.83% and homewear, thermal clothing, and underwear experiencing declines between 4% and 9% [3]. - The decline in revenue was attributed mainly to reduced foot traffic, with offline direct sales down 7.96% and online sales down 8.14% [4]. Dividend Policy - Despite poor overall performance, Aimer announced a substantial cash dividend of 4 yuan per 10 shares, totaling 99.55% of net profit, raising concerns about future funding reserves [4]. Cost Management - Aimer's sales expenses decreased by 4.42% due to reduced promotional spending, while management expenses increased by 6.33% due to higher personnel costs [4]. - The inventory level remained high at 982 million yuan, with a provision for inventory impairment at 21.85%, indicating significant inventory digestion pressure [4]. Strategic Adjustments - In response to performance challenges, Aimer is focusing on the sportswear segment by establishing dedicated divisions for the "Aimer Sports" and "Chichu" brands and accelerating channel restructuring [4]. - Although R&D investment decreased by 3.01%, Aimer added 58 new patents, including 26 Chinese invention patents [4].